GlobeNewswire

Introducing Ouriginal: An Authoritative European Voice in the Fight Against Plagiarism

Share

Announcing Ouriginal


The combined expertise, knowledge and innovation of these two Education Technology leaders promises to benefit educational institutions globally.

STOCKHOLM, Sweden and COLOGNE, Germany, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Ouriginal, the fusion of Europe's leading text matching solutions is announcing its official launch today. The new EdTech company is formed from the synthesis of Urkund and PlagScan, two established and trusted names in plagiarism detection. Combining expertise spanning decades, the award-winning software solutions are designed to enable educators and other users to assess the authenticity and originality of any text. The new organization offers the scale and structure to better respond to the growing needs of education and research globally. With a proven culture of high performance and cutting-edge technology, Ouriginal promises to take academic integrity to new levels, encouraging and fostering everyone’s original voice. 

Digital Sharing and Time Deficiency Pose Real Threat to Academic Integrity

The emergence of an interconnected and global digital economy poses significant challenges to student literacy.  Billions of digital content sources are openly and freely available to learners for use in research, whether it be a simple homework task, university assignments, PhD thesis, or a political speech. Additionally, with limited time and enormous availability of information, ghostwriters and essay mill services have emerged as a huge business and growing problem for educators.

“Many students are not aware that by not writing assignments themselves, they are ultimately harming their education. They are losing out on chances in life through developing their own original way of thinking and writing”, says Andreas Ohlson, CEO of Ouriginal. “Checking submissions manually is very time-consuming, so educators often refrain from it, or only check ‘suspicious’ texts. While it is understandable, it also creates an ‘unfair’ learning environment.”

Ouriginal Frees Up Time and Enables Educators to Focus on Students, Not Their Text

Learning Management Systems (LMS), are the educator’s toolbox and dashboard in today’s teaching environment. With remote learning becoming the new "normal", institutions are increasingly challenged in student development, academic integrity, and the quality of the students’ learning experience. Seamless integrations between technology solutions have become vital for teaching and learning. Ouriginal understands this challenge and is committed to partnerships with technology providers that require our expertise. Ouriginal is seamlessly integrated into all major LMS and a growing number of e-learning tools.

“In my experience, an effective e-learning solution shouldn’t be invasive or rigid. It needs to work within the ecosystem that drives the operation. It should be flexible, scalable, easy to use, and definitely shouldn’t hijack the workflow,” continues Andreas Ohlson. “At Ouriginal we work closely with our LMS and e-learning partners to ensure that our expertise fills their gaps, and leads to smart integrations and happy end-users.”

If you are interested in an interview with Andreas Ohlson, CEO of Ouriginal, please reach out to press@ouriginal.com to arrange a meeting or call. 

More information on Ouriginal can also be found at www.ouriginal.com

About Ouriginal
Ouriginal is a text-matching software used to assess the originality of any given text. It was born out of the fusion of PlagScan and Urkund with the goal to offer a bold solution that enhances students' potentials to think original and saves teachers time evaluating assignments. With more than 3 decades of combined knowledge and expertise, we deliver cutting-edge technology, catering to our customers' needs.

Contact
Head of Marketing
Verena Kunz-Gehrmann
Verena heads up marketing and communications at Ouriginal. She is the person to get in contact with if you want to know more about the Ouriginal story.
press@ouriginal.com
+49 (0) 1522 990 8956

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Incap Corporation: Notification in accordance with Chapter 9, Section 10 of the Securities Market Act on a Change in Holdings (Nordea Bank Abp)23.11.2020 20:30:00 CETPress release

Incap Corporation Stock Exchange Release 23 November 2020 at 9.30 p.m. (EET) Notification in accordance with Chapter 9, Section 10 of the Securities Market Act on a Change in Holdings (Nordea Bank Abp) Incap Corporation has on 23 November 2020 received a notification in accordance with the Securities Market Act, according to which the total holdings of shares and votes of Nordea Bank Abp and the entities controlled by it (Nordea Life Assurance Finland Ltd and Nordea Livförsäkring Sverige AB (publ)) in Incap Corporation (FI0009006407) has decreased below 10 percent threshold. Shareholder: Nordea Life Assurance Finland Ltd and Nordea Livförsäkring Sverige AB (publ) Position of previous notification: 14.7 % out of all shares and votes Date of change in holdings: 20 November 2020 Resulting situation on the date on which threshold was crossed: 581,835 shares, i.e. 10 % out of all shares and votes Incap Corporation's total number of shares amounts to 5,820,224 and each share has one vote. Af

EPH European Property Holdings Limited (EPH) announces plans to issue and offer up to 4,500,000 new ordinary shares23.11.2020 19:00:00 CETPress release

23 November 2020, Road Town, Tortola, BVI EPH European Property Holdings Ltd (the "Company"), an investment company listed on SIX Swiss Exchange which holds an extensive property portfolio with a total value of around USD 1.3 billion across Europe, announces its intention to issue and offer up to 4,500,000 new ordinary shares for a consideration equaling the last reported net asset value (as per 30 June 2020) in the amount of USD 38.82 per share (the "Offer Shares"). EPH will hold a virtual conference on Monday, 30 November 2020 at 3 pm CET to explain details of the capital increase and the company's strategy. You are welcome to register for this event. Please contact corporatefinance@valartis.chto receive dial-in data. The proceeds from the issue of the Offer Shares will be used for funding our future growth through, including, without limitation, the following: acquisition of additional income generating or to be developed commercial properties and investments in our existing real es

Idorsia announces positive results of the two Japanese registration studies with clazosentan23.11.2020 17:45:10 CETPress release

Clazosentan demonstrates significant reduction of vasospasm-related morbidity and all-cause mortality in patients following aneurysmal subarachnoid hemorrhage (aSAH)Clazosentan demonstrates significant reduction of all-cause morbidity and mortality in patients following aSAH in a pre-planned pooled analysis of data from both studies.Idorsia Japan to file New Drug Application (NDA) with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in the first half of 2021Global Phase 3 study “REACT” investigating the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in adult patients following aSAH continues to actively recruit Allschwil, Switzerland – November 23, 2020 Idorsia Ltd (SIX: IDIA) today announced positive top-line results of the Japanese registration program investigating clazosentan in adult Japanese patients post-aSAH. The program consisted of two double-blind, randomized, placebo-controlle

Saniona rapporterar positiva topline-resultat från den öppna förlängningen av Fas 2-studien med Tesomet mot hypotalamisk fetma23.11.2020 17:00:00 CETPressemelding

PRESSMEDDELANDE 23 november 2020 Tesomet tolererades väl av patienterna med hypotalamisk fetma under hela den 48 veckor långa studien (24 veckor dubbelblind del följt av 24 veckor öppen förlängning). Inga kliniskt betydelsefulla skillnader kunde noteras avseende hjärtfrekvens eller blodtryck och samtliga patienter som påbörjade den öppna förlängningsstudien slutförde också studien.De patienter som fick Tesomet under hela den 48 veckor långa studietiden påvisades statistiskt signifikanta och kliniskt meningsfulla minskningar av kroppsvikt och midjeomfång från baseline till vecka 48, liksom förbättrad glykemisk kontroll. De förbättringar som observerades under den första dubbelblinda delen av studien bibehölls under hela den senare öppna förlängningsstudien. Även för de patienter som fick placebo under den dubbelblinda delen av studien och sedan Tesomet under den öppna förlängningsstudien påvisades minskningar av kroppsvikt och midjeomfång efter övergången till Tesomet.Saniona kommer att

Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity23.11.2020 17:00:00 CETPress release

PRESS RELEASE November 23, 2020 Tesomet was well-tolerated in hypothalamic obesity patients throughout the duration of the 48-week trial (24 week double-blind [DB] followed by 24 week open label extension [OLE]), with no clinically meaningful differences in heart rate or blood pressure observed. All patients who entered the OLE study completed it.Patients receiving Tesomet for the full 48 weeks of the study demonstrated statistically significant and clinically meaningful reductions in body weight and waist circumference from baseline to Week 48, as well as improvements in glycemic control. Improvements observed in the DB period of the study were maintained over the duration of the OLE period. Patients who received placebo in the DB period of the study and were subsequently switched to Tesomet for the OLE period also achieved reductions in body weight and waist circumference after being switched to Tesomet.Saniona to host webcast with Dr. Ulla Feldt-Rasmussen on Tuesday, 24 November 202

Incap Corporation: Notification in accordance with chapter 9, section 10 of the securities market act on a change in holdings (Oy Etra Invest Ab)23.11.2020 16:30:00 CETPress release

Incap Corporation Stock Exchange Release 23 November 2020 at 5.30 p.m. (EET) Notification in accordance with Chapter 9, Section 10 of the Securities Market Act on a Change in Holdings (Oy Etra Invest Ab) Incap Corporation has on 23 November 2020 received a notification in accordance with the Securities Market Act, according to which the total holdings of shares and votes of Erkki Etola and the entities controlled by him (Tiiviste-Group Oy and Oy Etra Invest Ab) in Incap Corporation (FI0009006407) has increased over 20 percent threshold. Shareholder: Erkki Etola and entities controlled by him Position of previous notification: 19.20 % out of all shares and votes Date of change in holdings: 20 November 2020 Resulting situation on the date on which threshold was crossed: 1,327,333 shares, i.e. 22.81 % out of all shares and votes Incap Corporation's total number of shares amounts to 5,820,224 and each share has one vote. After November 20, 2020, Erkki Etola's direct holding of shares and v